Regeneron, Sanofi Expand Immunology Antibody Alliance

Regeneron and Sanofi are expanding their global alliance with the addition of REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody, and two other preclinical long-acting antibodies. Regeneron will receive $1 billion upfront with potential for future payments.